TED Ted Baker Plc

    26 November 2004

             Tepnel Life Sciences PLC (`Tepnel' or `the Company')              

                           Directors' Shareholdings                            

Manchester, UK. 26 November 2004 * The Company was notified today by Mr Alec
Craig, Non-Executive Chairman that in the recent placing he had purchased
350,000 ordinary shares of 1p each in the Company ("Ordinary Shares"), at a
price of 5.65 pence per share. Following this purchase, Mr Craig's total
holding in Tepnel amounts to 557,163 Ordinary Shares, representing
approximately 0.26 per cent. of the issued share capital of the Company.

The Company was notified today by Mr Ben Matzilevich, Chief Executive Officer,
that in the recent placing he had purchased 4,910,000 ordinary shares of 1p
each in the Company ("Ordinary Shares"), at a price of 5.65 pence per share.
Following this purchase, Mr Matzilevich's total holding in Tepnel amounts to
5,844,783 Ordinary Shares, representing approximately 2.75 per cent. of the
issued share capital of the Company.

The Company was notified today by Mr Gron Ffoulkes-Davies, Group Finance
Director, that in the recent placing he had purchased 3,000,000 ordinary shares
of 1p each in the Company ("Ordinary Shares"), at a price of 5.65 pence per
share. Following this purchase, Mr Ffoulkes-Davies' total holding in Tepnel
amounts to 3,750,000 Ordinary Shares, representing approximately 1.76 per cent.
of the issued share capital of the Company.

The Company was notified today by Mr Andrew Clark, Non-Executive Director, that
in the recent placing he had purchased 1,061,000 ordinary shares of 1p each in
the Company ("Ordinary Shares"), at a price of 5.65 pence per share. Following
this purchase, Mr Clark's total holding in Tepnel amounts to 1,061,000 Ordinary
Shares, representing approximately 0.50 per cent. of the issued share capital
of the Company.

The Company was notified today by Mr Don Marvin, Non-Executive Director, that
in the recent placing he had purchased 490,000 ordinary shares of 1p each in
the Company ("Ordinary Shares"), at a price of 5.65 pence per share. Following
this purchase, Mr Marvin's total holding in Tepnel amounts to 518,000 Ordinary
Shares, representing approximately 0.24 per cent. of the issued share capital
of the Company.

For Further Information:

Tepnel Life Sciences plc
Ben Matzilevich, CEO

Gron Ffoulkes-Davies, Finance Director

0161 946 2200

Seymour Pierce

Mark Percy, Corporate Finance

0207 107 8000

De Facto Communications

Helena Podd

020 7940 1000

Notes to Editors

About Tepnel Life Sciences plc

Tepnel is a UK-based international life sciences instrumentation and services
company with a `tri-polar' strategy focused on providing the biomedical
industry with high-throughput automated DNA purification systems, manual DNA
purification kits and reagents, as well as scientific services for nucleic acid
purification, drug analysis, genotyping and genetically modified foods. Tepnel
was founded in 1992 to exploit DNA technology generated at UMIST (University of
Manchester Institute of Science and Technology) and is quoted on the AIM
segment of the London Stock Exchange (AIM: TED). More information on Tepnel can
be found at www.tepnel.com.



END

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024